SAVANNAH: Safety and tolerability of osimertinib (osi) plus savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi

  • Chu, Q. S. C.; 
  • De Marinis, F.; 
  • Levy, B.; 
  • Bonanno, L.; 
  • Cheng, S.; 
  • 외 15명
Citations

WEB OF SCIENCE

0
제목
SAVANNAH: Safety and tolerability of osimertinib (osi) plus savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi
저자
Chu, Q. S. C.; De Marinis, F.; Levy, B.; Bonanno, L.; Cheng, S.; Sacher, A.; Proto, C.; Novello, S.; Luo, Y-H; Baik, C. S.; Bazhenova, L.; Yang, C. T.; Shimizu, J.; Riess, J. W.; Leventakos, K.; Nelson, S.; Igwegbe, I.; Haskins, M.; Xu, W.; Ahn, M-J
DOI
10.1016/j.annonc.2025.08.2579
발행일
2025-09
유형
Meeting Abstract
저널명
Annals of Oncology
권
36